News Novartis aims to broaden use of breast cancer drug Study shows Kisqali extends survival in younger women with aggressive disease
News NICE rejects Eisai's Halaven in new breast cancer use NICE rejects drug after finding gap in clinical data
News Samsung Bioepis Herceptin biosimilar approved in EU Mylan and Biocon resolve biosimilar manufacturing issues
News NICE backs funding for Pfizer, Novartis breast cancer drugs Pfizer had been giving drug free to NHS before decision
News Lilly’s Verzenio joins breast cancer market The FDA has approved Lilly’s Verzenio, making it the third market entrant in a new class of drugs for breast cancer.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
